Trial reportScientific reports2026
The short-term effect of near infrared irradiation on arteriovenous fistula in hemodialysis patients: a pilot, prospective study.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arteriovenous fistula (AVF) is the preferred vascular access for maintenance hemodialysis (MHD) patients. This is a pilot trial evaluates short-term near-infrared (NIR) therapy for AVF in MHD patients. Between July and September 2023, 60 MHD patients at Peking University Third Hospital were screened. Of these, 44 were enrolled and randomized, and 42 completed the study. The JLP-800 infrared therapy device (Input voltage 220 V, oscillation mode, wavelength 600–3400 nm, 0–21 W output, the output power is 70%, and the energy density is 31.8 J/cm2) was used to illuminate AVF for 30-min. The safety index was the skin temperature of the AVF. Hemodynamic alterations and regional biomarker profiles were assessed via intention-to-treat analysis with longitudinal pre-/post-NIR exposure comparisons. The results demonstrated the safety of NIR for AVFs. The Interleukin‑6 (IL‑6) on AVF and systemic level of NIR group decreased significantly compared to controls [ -0.46 pg/mL (IQR: -1.84 to 0.19) versus + 0.23 pg/mL (IQR: -0.23 to 0.79); -0.53 pg/mL (IQR: -2.05 to 0.07) versus + 0.86 pg/mL (IQR: -0.37 to 4.27)]. After 30-min, theinterleukin‑10 (IL‑10) on the AVF in the NIR group increased significantly. Compared with the control group, the rise in interleukin‑8 (IL‑8)on the AVF of NIR was more modest. The CD4+/CD8 + on the AVF and systemic increased significantly in NIR group [1.48(0.00,2.84) vs. 2.07(0.55,3.48), P < 0.05; 1.66(0.00, 2.71) vs. 1.94(0.60, 3.80), P < 0.05]. This pilot study suggests that short-term NIR irradiation of the AVF in hemodialysis patients appears to be safe and may potentially attenuate the inflammatory response to some extent.Clinical trial registration number: ChiCTR2300071305 (05/10/2023).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.